Reishi mushroom is a natural product that may enhance immunity and response to chemo/radiotherapy, improve quality of life, and manage some side effects. 

Are you a health professional?

This section does not replicate the other information on this topic but provides additional details or context most relevant to professionals.

Modes of action

Studies suggest that the anti-tumor activities of G. lucidum polysaccharide (GLPS) are mediated by its immunomodulatory, anti-angiogenic, and cytotoxic effects. GLPS affects immune cells and immune-related cells including B lymphocytes, T lymphocytes, dendritic cells, macrophages, and natural killer cells.1Xu Z, Chen X, Zhong Z, Chen L, Wang Y. Ganoderma lucidum polysaccharides: immunomodulation and potential anti-tumor activities. American Journal of Chinese Medicine. 2011;39(1):15-27. 

Network pharmacology revealed that key targets of G. lucidum against endometrial cancer were primarily associated with the Rap1 signaling pathway.2Shi M. The efficacy of Ganoderma lucidum extracts on treating endometrial cancer: a network pharmacology approach. Reproductive Sciences. 2024 Jul;31(7):1881-1894.

Androgen receptor, nuclear factor-kappa B, activator protein-1, p53 and 14-3-3 are reportedly involved in the anticancer properties of G. lucidum triterpenoids.3Wu GS, Guo JJ et al. Anti-cancer properties of triterpenoids isolated from Ganoderma lucidum—a review. Expert Opinion on Investigational Drugs. 2013 Aug;22(8):981-92. 

Ganoderic acids might exert their cytotoxicity by altering proteins involved in cell proliferation and/or cell death, carcinogenosis, oxidative stress, calcium signaling, and ER stress.4Yue QX, Song XY et al. Effects of triterpenes from Ganoderma lucidum on protein expression profile of HeLa cells. Phytomedicine. 2010 Jul;17(8-9):606-13.

More on safety

One cell study found toxic effects of reishi mushrooms on human leukocytes.5Gill SK, Rieder MJ. Toxicity of a traditional Chinese medicine, Ganoderma lucidum, in children with cancer. Canadian Journal of Clinical Pharmacology. 2008 Summer;15(2):e275-85. and another study found that “both submerge-cultured intracellular GLP and fruiting body GLP can stimulate the growth of human carcinoma cell lines lacking functional p53, such as HCT-116 p53(-/-), Saos-2, H1299, HL-60, MDA-MB-157. Conversely, the two GLPs inhibit all other assayed cells with functional p53.”6Zhang J, Chen JM et al. Inhibitor or promoter? The performance of polysaccharides from Ganoderma lucidum on human tumor cells with different p53 statuses. Food & Function. 2016 Apr;7(4):1872-5.

Preclinical evidence

The strongest preclinical studies for various types of cancer are presented here. Clinical evidence is presented in How can reishi mushroom help you? What the research says ›

Improving treatment outcomes

Cancer as a whole
  • Nanoparticles loaded with G. lucidum polysaccharide at 6 µg/ml and chitosan/sodium tripolyphosphate (mass) ratio of 5.5 had significantly greater cytotoxic effects on tumor cells.7Li N, Hu YL et al. Preparation, characterisation and anti-tumour activity of Ganoderma lucidum polysaccharide nanoparticles. Journal of Pharmacy and Pharmacology. 2010 Jan;62(1):139-44.
Bile duct cancer cancer (cholangiocarcinoma)
Bladder cancer
  • Reishi inhibited the viability and growth of human urothelial cells.12Yuen JW, Gohel MD, Au DW. Telomerase-associated apoptotic events by mushroom ganoderma lucidum on premalignant human urothelial cells. Nutrition and Cancer. 2008;60(1):109-19.
  • Reishi extracts inhibited the growth of human urothelial cells, and ethanol extracts had a stronger growth inhibition effect than water extracts.13Lu QY, Jin YS et al. Ganoderma lucidum extracts inhibit growth and induce actin polymerization in bladder cancer cells in vitro. Cancer Letters. 2004 Dec 8;216(1):9-20.
Blood cancers
Brain and nervous system cancers
  • Anaplastic meningioma: Reishi produced lower tumor volume, less tumor cell proliferation, and longer survival in rats.16Das A, Alshareef M et al. Ganoderic acid A/DM-induced NDRG2 over-expression suppresses high-grade meningioma growth. Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2020 Jul;22(7):1138-1145.
  • Glioma: Reishi produced slower tumor development and longer survival in rats.17Wang C, Shi S et al. Antitumor and immunomodulatory activities of Ganoderma lucidum polysaccharides in glioma-bearing rats. Integrative Cancer Therapies. 2018 Sep;17(3):674-683.
  • Glioblastoma: Ganoderic acid A isolated from reishi mushrooms inhibited human glioblastoma cell growth and invasion/migration and promoted apoptosis and autophagy.18Cheng Y, Xie P. Ganoderic acid A holds promising cytotoxicity on human glioblastoma mediated by incurring apoptosis and autophagy and inactivating PI3K/AKT signaling pathway. Journal of Biochemical and Molecular Toxicology. 2019 Nov;33(11):e22392.
  • Neuroblastoma: Ganoderic acid isolated from reishi mushrooms exhibited downregulation in Notch-1 mRNA expression and inhibited proliferation, viability, and ROS activity in neuroblastoma cells.19Gill BS, Navgeet, Kumar S. Antioxidant potential of ganoderic acid in Notch-1 protein in neuroblastoma. Molecular and Cellular Biochemistry. 2019 Jun;456(1-2):1-14.
Breast cancer
Colorectal cancer
Esophageal cancer
Gynecologic cancer

Cervical cancer:

Endometrial cancer

Liver cancer
Lung cancer
Melanoma and other skin cancers
Nasopharyngeal cancer
  • Lucialdehyde B (LB), a triterpenoid isolated from reishi mushroom, suppressed proliferation and induced mitochondrial-dependent apoptosis in nasopharyngeal carcinoma CNE2 cells.51Liu L, Yu Z et al. Lucialdehyde B suppresses proliferation and induces mitochondria-dependent apoptosis in nasopharyngeal carcinoma CNE2 cells. Pharmaceutical Biology. 2023 Dec;61(1):918-926. 
Oral cancer
Ovarian cancer
Prostate cancer
  • Reishi polysaccharide synergistically increased the effect of docetaxel and flutamide and increased the sensitivity of the prostate cancer cell lines to these drugs.55Rahimnia R, Akbari MR et al. The effect of Ganoderma lucidum polysaccharide extract on sensitizing prostate cancer cells to flutamide and docetaxel: an in vitro study. Scientific Reports. 2023 Nov 2;13(1):18940.
  • A high dose (2 mg/ml) of triterpenes from reishi mushrooms inhibited prostate cancer cell viability in a dose- and time-dependent manner.56Qu L, Li S et al. Anticancer effect of triterpenes from Ganoderma lucidum in human prostate cancer cells. Oncology Letters. 2017 Dec;14(6):7467-7472.
  • Reishi ethanol extracts decreased androgen and glucocorticoide receptors transcriptional activity in breast cancer MDA-kb2 cells in a dose-dependent manner, and suppressed androgen receptor (AR) protein level in prostate cancer cells.57Zaidman BZ, Wasser SP, Nevo E, Mahajna J. Coprinus comatus and Ganoderma lucidum interfere with androgen receptor function in LNCaP prostate cancer cells. Molecular Biology Reports. 2008 Jun;35(2):107-17.
  • Reishi led to less adhesion and migration of highly invasive prostate cancer cells.58Sliva D. Ganoderma lucidum (reishi) in cancer treatment. Integrative Cancer Therapies. 2003 Dec;2(4):358-64.
Sarcoma
Stomach cancer
  • Reishi mushroom suppressed Epstein-Barr virus-associated gastric carcinoma tumor development in mice, which was enhanced by cotreatment with quercetin.64Huh S, Lee S et al. Quercetin synergistically inhibit EBV-associated gastric carcinoma with Ganoderma lucidum extracts. Molecules. 2019 Oct 24;24(21):3834.

Optimizing body terrain

Reishi mushroom modulates the immune system.66Zhao SL, Nie YZ, Liang GN, Chen LL, Hou YY. Ganoderma lucidum polysaccharides combined with low-dose cisplatin inhibits tumor growth and enhances the immune function of tumor-bearing mice. International Journal of Traditional Chinese Medicine. 2012;34(12):1084–7; Lian S, Li W et al. Ganoderma lucidum spore oil synergistically enhances the function of cyclophosphamide in the prevention of breast cancer metastasis. Journal of the Chinese Medical Association. 2024 Mar 1;87(3):305-313; Liao SF, Liang CH et al. Immunization of fucose-containing polysaccharides from reishi mushroom induces antibodies to tumor-associated Globo H-series epitopes. Proceedings of the National Academy of Sciences of the USA. 2013 Aug 20;110(34):13809-14; Wang YY, Khoo KH et al. Studies on the immuno-modulating and antitumor activities of Ganoderma lucidum (Reishi) polysaccharides: functional and proteomic analyses of a fucose-containing glycoprotein fraction responsible for the activities. Bioorganic & Medicinal Chemistry. 2002 Apr;10(4):1057-62. Reishi extracts can significantly inhibit the release of IL-8, IL-6, MMP-2, and MMP-9 in melanoma and breast cancer cells under pro-inflammatory conditions.67Barbieri A, Quagliariello V et al. Anticancer and anti-inflammatory properties of Ganoderma lucidum extract effects on melanoma and triple-negative breast cancer treatment. Nutrients. 2017 Feb 28;9(3). pii: E210. Ling Zhi-8 (LZ-8), a protein isolated from reishi mushrooms, enhanced the immune response of HER-2/neu DNA vaccine against p185neu expressing tumor MBT-2 in mice.68Lin CC, Yu YL et al. A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells. Cancer Immunology, Immunotherapy. 2011 Jul;60(7):1019-27.

One study found that the mode of extraction of medicinal mushrooms may determine the nature of the immunomodulatory effects on immune cells, presumably owing to the differential solubility of stimulatory and inhibitory mediators. Water extracts enhance NK cell cytotoxic activity against cancer cells, whereas ethanol extracts inhibit cytotoxicity.69Lu CC, Hsu YJ et al. Immunomodulatory properties of medicinal mushrooms: differential effects of water and ethanol extracts on NK cell-mediated cytotoxicity. Innate Immunity. 2016 Oct;22(7):522-33.

Reishi also shows these terrain properties:

Managing side effects and promoting wellness

Blood-related side effects
Cardiovascular symptoms
Changes in appetite
  • Reishi improved appetite and general health in rats.79Wang CZ, Basila D et al. Effects of ganoderma lucidum extract on chemotherapy-induced nausea and vomiting in a rat model. American Journal of Chinese Medicine. 2005;33(5):807-15.
Cognitive difficulties
Gastrointestinal effects

Nausea and vomiting:

  • Reishi reduced nausea and vomiting in rats.81Wang CZ, Basila D et al. Effects of ganoderma lucidum extract on chemotherapy-induced nausea and vomiting in a rat model. American Journal of Chinese Medicine. 2005;33(5):807-15.

Small intestinal damage:

Liver toxicity:

Kidney toxicity
Lung toxicity
Pain
Radiation damage
  • Reishi aqueous extracts reduce radiation damage in animals.89González A, Atienza V, Montoro A, Soriano JM. Use of Ganoderma lucidum (Ganodermataceae, Basidiomycota) as radioprotector. Nutrients. 2020 Apr 19;12(4):1143.
Sleep disruption
  • Reishi extracts promoted sleep in freely moving rats.90Cui XY, Cui SY et al. Extract of Ganoderma lucidum prolongs sleep time in rats. Journal of Ethnopharmacology. 2012 Feb 15;139(3):796-800. 
  • A reishi aqueous extract decreased sleep latency, increased sleeping time, non-REM sleep time, and light sleep time in phentobarbital-treated rats, but had no effect on untreated rats.91Chu QP, Wang LE et al. Extract of Ganoderma lucidum potentiates pentobarbital-induced sleep via a GABAergic mechanism. Pharmacology, Biochemistry, and Behavior. 2007 Apr;86(4):693-8.

Reducing cancer risk

Solid tumors
  • Reishi polysaccharides inhibited tumor volume and tumor mass in animals when administered prior to tumor inoculation in animals.92Joseph S, Sabulal B, George V, Antony KR, Janardhanan KK. Antitumor and anti-inflammatory activities of polysaccharides isolated from Ganoderma lucidum. Acta Pharmaceutica. 2011 Sep 1;61(3):335-42. 
Bladder cancer
Colorectal cancer
Prostate cancer

Helpful links for professionals

Keep reading about reishi mushroom

Authors

Nancy Hepp, MS

Lead Researcher
View profile

Ms. Hepp is a researcher and communicator who has been writing and editing educational content on varied health topics for more than 20 years. She serves as lead researcher and writer for CancerChoices and also served as the first program manager. Her graduate work in research and cognitive psychology, her master’s degree in instructional design, and her certificate in web design have all guided her in writing and presenting information for a wide variety of audiences and uses. Nancy’s service as faculty development coordinator in the Department of Family Medicine at Wright State University also provided experience in medical research, plus insights into medical education and medical care from the professional’s perspective.

Nancy Hepp, MS Lead Researcher

Maria Williams

Research and Communications Consultant
View profile

Maria Williams is a research and communications consultant who brings over 15 years’ experience in research, consumer education, and science communication to CancerChoices. She has worked primarily in public health and environmental health.

Maria Williams Research and Communications Consultant

Laura Pole, MSN, RN, OCNS

Senior Clinical Consultant
View profile

Laura Pole is senior clinical consultant for CancerChoices. Laura is an oncology clinical nurse specialist who has been providing integrative oncology clinical care, navigation, consultation, and education services for over 40 years. She is the co-creator and co-coordinator of the Integrative Oncology Navigation Training at Smith Center for Healing and the Arts in Washington, DC. Laura also manages the “Media Watch Cancer News That You Can Use” listserv for Smith Center/Commonweal. In her role as a palliative care educator and consultant, Laura has served as statewide Respecting Choices Faculty for the Virginia POST (Physician Orders for Scope of Treatment) Collaborative as well as provided statewide professional education on palliative and end-of-life care for the Virginia Association for Hospices and Palliative Care.

For CancerChoices, Laura curates content and research, networks with clinical and organizational partners, brings awareness and education of integrative oncology at professional and patient conferences and programs, and translates research into information relevant to the patient experience as well as clinical practice.

Laura sees her work with CancerChoices as a perfect alignment of all her passions, knowledge and skills in integrative oncology care. She is honored to serve you.

Laura Pole, MSN, RN, OCNS Senior Clinical Consultant

Reviewer

Andrew Jackson, ND

Research Associate
View profile

Andrew Jackson, ND, serves as a CancerChoices research associate. As a naturopathic physician practicing in Kirkland, Washington, he teaches critical evaluation of the medical literture at Bastyr University in Kenmore, Washington. His great appreciation of scientific inquiry and the scientific process has led him to view research with a critical eye.

Andrew Jackson, ND Research Associate

Last update: September 18, 2024

Last full literature review: July 2024

CancerChoices provides information about integrative in cancer care, a patient-centered approach combining the best of conventional care, self care and evidence-informed complementary care in an integrated plan cancer care. We review complementaryin cancer care, complementary care involves the use of therapies intended to enhance or add to standard conventional treatments; examples include supplements, mind-body approaches such as yoga or psychosocial therapy, and acupuncture therapies and self-care lifestyle actions and behaviors that may impact cancer outcomes; examples include eating health-promoting foods, limiting alcohol, increasing physical activity, and managing stress practices to help patients and professionals explore and integrate the best combination of conventionalthe cancer care offered by conventionally trained physicians and most hospitals; examples are chemotherapy, surgery, and radiotherapy and complementary therapies and practices for each person.

Our staff have no financial conflicts of interest to declare. We receive no funds from any manufacturers or retailers gaining financial profit by promoting or discouraging therapies mentioned on this site.

Learn more

Health professional comment

We invite health professionals to contribute expertise or send us questions.

"*" indicates required fields

Please share your thoughts about content on the CancerChoices website. If you have a correction for us to consider, or additional information to add, please include references and links if possible.

References[+]